Scholar Rock (SRRK) Soars 29% as Drug Candidate Progresses
In an announcement last week, Scholar Rock Holding Corp.
Scholar Rock Holding Corp (SRRK)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Siren L.L.C. Raymond Debbane | 10,825,013 | $476,841,823 | +18% | 14.22% |
| 2. | Samsara BioCapital Srini Akkaraju And Michael Dybbs | 6,897,652 | $303,841,571 | +23% | 31.35% |
| 3. | Redmile Group Jeremy Green | 5,220,846 | $229,978,266 | +34% | 16.94% |
| 4. | Orbis Investment Management William B. Gray | 3,428,929 | $151,044,322 | +1035% | 0.63% |
| 5. | Paradigm Biocapital Advisors Senai Asefaw | 3,062,157 | $134,888,016 | +53% | 3.44% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.97 | 4,403 | $180,390.91 | 530,038 | 2025-10-07 | Filing | |
| $40.18 | 12,400 | $498,232.00 | 525,635 | 2025-10-07 | Filing | |
| $39.31 | 12,796 | $503,010.76 | 513,235 | 2025-10-07 | Filing | |
| $39.52 | 13,748 | $543,320.96 | 500,439 | 2025-10-06 | Filing | |
| $38.68 | 80,863 | $3,127,780.84 | 486,691 | 2025-10-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $46.53 | 4,157 | $193,417.73 | 126,012 | 2026-02-17 | Filing | |
| $46.53 | 9,580 | $445,740.16 | 241,545 | 2026-02-17 | Filing | |
| $46.53 | 9,035 | $420,382.29 | 169,087 | 2026-02-17 | Filing | |
| $46.53 | 7,989 | $371,713.79 | 106,929 | 2026-02-17 | Filing | |
| $46.85 | 12,779 | $598,748.54 | 85,660 | 2026-01-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,380,675 | $677,518,734 | 0.03% | |
| 2. | 7,217,034 | $317,910,349 | 0.01% | |
| 3. | 5,759,428 | $253,702,804 | 0.04% | |
| 4. | 5,195,465 | $228,860,234 | 0% | |
| 5. | 4,056,592 | $178,692,878 | 3.39% |
News See All
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2025 Earnings Call Transcript November 14, 2025Scholar Rock Holding Corporation misses on earnings expectations.
Scholar Rock (SRRK) Climbs 24% on Drug Candidate Progress
In an updated report, Scholar Rock Holding Corp.
Can Apitegromab Approval Turn Scholar Rock (SRRK) Into the Next Biotech Multibagger?
Scholar Rock Holding Corp. (NASDAQ:SRRK) is one of the best multibagger stocks to invest in right now.
15 Best Multibagger Stocks to Invest in Right Now
Just as a single diamond can outshine a handful of pebbles, a well-chosen multibagger can transform an ordinary portfolio into an extraordinary one.
Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD
In the second quarter of the year, Scholar Rock Holding Corp. (NASDAQ:SRRK) saw its net loss widen by 89.6 percent to $110 million from $58 million in the same period last year.
Scholar Rock's Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss
Scholar Rock Holding Corporation (NASDAQ:SRRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in.
11 Best GLP-1 and Weight Loss Stocks to Invest in
GLP-1 medicines are a type of prescription that mimics a natural hormone that regulates blood sugar and appetite.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q2 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q2 2025 Earnings Call Transcript August 6, 2025Scholar Rock Holding Corporation misses on earnings expectations.
Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial
In a statement, Scholar Rock Holding Corporation (NASDAQ:SRRK) said the trial, which aims to assess its drug candidate apitegromab’s combination with tirzepatide, was generally well tolerated, leading...
Hedge Fund Resource Center